Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CRON
CRON logo

CRON Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.580
Open
2.520
VWAP
2.54
Vol
946.67K
Mkt Cap
955.21M
Low
2.510
Amount
2.40M
EV/EBITDA(TTM)
--
Total Shares
379.05M
EV
179.11M
EV/OCF(TTM)
6.92
P/S(TTM)
6.63
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
Show More

Events Timeline

(ET)
2026-02-26
07:50:00
Cronos Reports FY25 Net Revenue of $146.6M
select
2026-02-17 (ET)
2026-02-17
07:40:00
Cronos Group Launches New Spinach PUFFERZ Vape
select
2025-12-26 (ET)
2025-12-26
13:40:00
Trump Reaches Agreements with Pharma Companies to Lower Drug Prices
select
2025-12-24 (ET)
2025-12-24
09:50:00
Trump Delays New Tariffs on Chinese Chips for 18 Months
select
2025-12-23 (ET)
2025-12-23
15:10:00
Trump Instructs Attorney General to Expedite Marijuana Rescheduling
select
link
2025-12-19 (ET)
2025-12-19
10:10:00
Trump Signs Executive Order on Marijuana Research to Improve CBD Access
select
2025-12-18 (ET)
2025-12-18
16:30:00
Major Averages Rise as CPI Data Surprises Investors
select
2025-12-18
15:40:00
Trump Signs Executive Order to Reclassify Cannabis as Schedule III Drug
select

News

seekingalpha
9.5
02-26seekingalpha
Cronos Group Reports Record Growth in 2025 Earnings Call
  • Significant Revenue Growth: Cronos Group reported a consolidated net revenue of $44.5 million for Q4 2025, reflecting a 47% year-over-year increase driven by strong cannabis flower sales in Israel and Canada, underscoring the continued strength of its core business.
  • Market Leadership Reinforced: The Spinach brand emerged as the second-largest vape brand in Canada and achieved the top market share in vape cartridges, further solidifying the company's leadership position in the rapidly growing consumer goods market.
  • Strategic Acquisition Plans: The company announced a definitive agreement to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for €57.5 million (approximately $67.5 million), with closing expected in H1 2026, which will provide robust support for the company's expansion into the European market.
  • Strong Financial Position: Cronos Group maintains the strongest balance sheet in the industry with no debt and $832 million in cash and short-term investments, demonstrating the company's financial flexibility for future expansions and acquisitions.
seekingalpha
9.5
02-26seekingalpha
Cronos Reports Q4 Revenue Beat Despite Net Loss
  • Significant Revenue Growth: Cronos reported $44.5 million in revenue for Q4 2025, reflecting approximately 47% year-over-year growth, exceeding market expectations by $5.8 million, primarily driven by improved flower sales in multiple countries, including Israel.
  • Gross Profit Increase: The company's gross profit rose nearly 50% year-over-year to $16.2 million, indicating enhanced sales volumes and average selling prices, although overall performance was impacted by foreign currency transaction losses.
  • Net Loss Reported: Despite revenue growth, Cronos swung to a net loss of $0.5 million from a net income of $43.9 million in the prior-year period, highlighting the significant impact of foreign exchange losses on the company's financials.
  • Annual Financial Overview: For the full year, Cronos posted a net loss of $9.4 million on $146.6 million in revenue, indicating approximately 25% year-over-year growth, while cash and cash equivalents fell about 8% year-over-year to $791.8 million, reflecting financial pressures amid market expansion efforts.
seekingalpha
9.5
02-26seekingalpha
Cronos Group Q4 Earnings Beat Expectations with Strong Revenue Growth
  • Earnings Highlights: Cronos Group reported a Q4 GAAP EPS of $0.00, missing expectations by $0.02; however, revenue reached $44.53 million, reflecting a 47% year-over-year increase and exceeding market expectations by $5.78 million, indicating strong revenue growth.
  • Adjusted EBITDA Improvement: The adjusted EBITDA for Q4 was $0.5 million, improving by $7.7 million from Q4 2024, primarily driven by higher adjusted gross profit, showcasing significant progress in cost control and profitability.
  • Geographic Expansion Strategy: Supported by a strong balance sheet, Cronos Group is actively pursuing geographic expansion to enhance market share and brand influence, particularly in the rapidly growing legal cannabis market.
  • Competitive Advantage: Cronos Group boasts a standout balance sheet compared to its peers, strengthening its competitive position in the industry and providing a relatively safe investment option amid future market fluctuations.
Yahoo Finance
9.5
02-26Yahoo Finance
Cronos Group Reports Fourth Quarter Loss
  • Quarterly Loss: Cronos Group reported a swing to a loss in the fourth quarter, indicating pressure from market competition that may undermine investor confidence.
  • Stock Price Decline: The stock fell 4% in U.S. pre-market trading, reflecting negative market sentiment regarding its financial performance, which could lead to short-term capital outflows.
  • Market Environment Challenges: The company faces intense industry competition and regulatory pressures, impacting its profitability and creating uncertainty around future growth prospects.
  • Investor Attention: Investors should closely monitor the company's strategic adjustments and market responses to assess its long-term investment value and potential returns.
Newsfilter
9.5
02-26Newsfilter
Cronos Group Reports Record Revenue in 2025 Financial Results
  • Revenue Growth: In Q4 2025, net revenue reached $44.5 million, a 47% year-over-year increase, while full-year revenue was $146.6 million, up 25%, reflecting strong consumer demand and positive market expansion impacts.
  • Gross Margin Improvement: Q4 2025 gross profit was $16.2 million, a 50% increase year-over-year, with full-year gross profit at $62.8 million, up 149%, primarily driven by higher sales prices and volumes in Israel and other countries.
  • International Market Expansion: Cronos GrowCo significantly contributed $10.3 million in flower sales for the full year 2025, enhancing the company's growth in international markets, particularly with sustained market share increases in Israel.
  • Strategic Acquisition Plans: The company plans to acquire CanAdelaar for $67.5 million, further solidifying its market position in Europe and expected to enhance its competitiveness in the Netherlands' legal adult-use cannabis market.
seekingalpha
9.5
02-25seekingalpha
Cronos Group to Announce Q4 Earnings on February 26
  • Earnings Announcement Schedule: Cronos Group is set to release its Q4 earnings on February 26 before the market opens, with consensus EPS estimates at $0.02 and revenue expectations of $38.75 million, reflecting a robust 27.9% year-over-year growth that indicates strong recovery potential in the market.
  • Financial Health: The company boasts a standout balance sheet among its peers, providing solid financial backing for its geographic expansion strategy, which is expected to further enhance its competitive position in the cannabis industry.
  • Market Expectation Analysis: As discussions around cannabis rescheduling gain momentum, Cronos is viewed as a safer investment option, attracting investor interest that may be reflected in its upcoming earnings report, showcasing its advantageous market positioning.
  • Historical Performance Review: Historical earnings data indicates that Cronos Group has maintained stable performance, boosting investor confidence in its future growth, particularly amid the rapid changes in the cannabis sector.
Wall Street analysts forecast CRON stock price to rise
2 Analyst Rating
Wall Street analysts forecast CRON stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
2.30
Averages
2.72
High
3.14
Current: 0.000
sliders
Low
2.30
Averages
2.72
High
3.14
TD Securities
NULL -> Buy
initiated
$4.50
AI Analysis
2026-02-24
Reason
TD Securities
Price Target
$4.50
AI Analysis
2026-02-24
initiated
NULL -> Buy
Reason
TD Securities initiated coverage of Cronos Group with a Buy rating and C$4.50 price target. Cronos, which has "some of the most iconic Canadian cannabis brands on the market, is well-positioned to improve profitability as it scales the top-line with a lean operating cost base and leading cultivation practices, the analyst tells investors.
Canaccord
Kenric Tyghe
Buy
initiated
$4.25
2026-01-27
Reason
Canaccord
Kenric Tyghe
Price Target
$4.25
2026-01-27
initiated
Buy
Reason
Canaccord analyst Kenric Tyghe initiated coverage of Cronos Group with a Buy rating and C$4.25 price target. While Canada and Israel are the company's two largest markets today, the firm believes that its recent acquisition of CanAdelaar and the expansion of Cronos Growing Company are "the leading edge of transformational change at the company," the analyst tells investors in a note starting coverage of the the Canadian cannabis group.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CRON
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cronos Group Inc (CRON.O) is 37.84, compared to its 5-year average forward P/E of 389.83. For a more detailed relative valuation and DCF analysis to assess Cronos Group Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
389.83
Current PE
37.84
Overvalued PE
1623.76
Undervalued PE
-844.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.17
Current EV/EBITDA
8.27
Overvalued EV/EBITDA
9.39
Undervalued EV/EBITDA
-11.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
11.20
Current PS
5.25
Overvalued PS
20.10
Undervalued PS
2.29

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

Should I Buy cannabis stocks?
Intellectia · 9 candidates
Market Cap: >= 50.00MThemes: The Cannabis IndustryList Exchange: XNYS, XNASMonthly Average Dollar Volume: >= 100,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
what cannabis stocks would you buy?
Intellectia · 4 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryQuarter Revenue Yoy Growth: >= 0.0%Monthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
SNDL logo
SNDL
SNDL Inc
386.25M
ACB logo
ACB
Aurora Cannabis Inc
204.15M
cannabis
Intellectia · 8 candidates
Market Cap: >= 200.00MPrice: >= $1.00Themes: The Cannabis IndustryIs Optionable: TrueMonthly Average Dollar Volume: >= 200,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
4.06B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.29B
CRON logo
CRON
Cronos Group Inc
1.01B
TLRY logo
TLRY
Tilray Brands Inc
874.97M
CGC logo
CGC
Canopy Growth Corp
440.50M
SNDL logo
SNDL
SNDL Inc
386.25M
best penny stocks to buy
Intellectia · 45 candidates
Market Cap: 50.00M - 1000.00MRegion: USPrice: $0.20 - $5.00Eps Ttm: >= 0Beta: ModerateRisk, HighRiskList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
HIVE logo
HIVE
HIVE Digital Technologies Ltd
695.26M
REI logo
REI
Ring Energy Inc
246.60M
GAU logo
GAU
Galiano Gold Inc
691.04M
LDI logo
LDI
loanDepot Inc
726.45M
ITRG logo
ITRG
Integra Resources Corp
671.92M
MVST logo
MVST
Microvast Holdings Inc
859.84M
marijuana stocks
Intellectia · 8 candidates
Market Cap: >= 200.00MRegion: US, CanadaPrice: >= $1.00Themes: The Cannabis IndustryList Exchange: XNYS, XNAS, XASEIs Optionable: TrueMonthly Average Dollar Volume: >= 300,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
CGC logo
CGC
Canopy Growth Corp
460.70M
SNDL logo
SNDL
SNDL Inc
406.85M
which. cannabisindustry should I invest in
Intellectia · 2 candidates
Market Cap: >= 500.00MThemes: The Cannabis IndustryWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
whats the best penny stocks to invest into
Intellectia · 25 candidates
Market Cap: <= 1000.00MPrice: <= $5.00Eps Ttm: >= 0Weekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
CRON logo
CRON
Cronos Group Inc
999.35M
GOGO logo
GOGO
Gogo Inc
642.50M
TALK logo
TALK
Talkspace Inc
632.81M
DDL logo
DDL
Dingdong (Cayman) Ltd
602.62M
NPWR logo
NPWR
NET Power Inc
575.35M
VTEX logo
VTEX
VTEX
573.92M
Cannibus stocks
Intellectia · 4 candidates
Market Cap: >= 500.00MThemes: The Cannabis IndustryBeta: ModerateRisk, HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SMG logo
SMG
Scotts Miracle-Gro Co
3.70B
IIPR logo
IIPR
Innovative Industrial Properties Inc
1.41B
TLRY logo
TLRY
Tilray Brands Inc
1.01B
CRON logo
CRON
Cronos Group Inc
999.35M
stocks under $5 today worth buying
Intellectia · 41 candidates
Market Cap: >= 300.00MPrice: <= $5.00Beta: ModerateRiskWeekly Average Turnover: >= 1,000,000Rsi 14: 30 - 70
Ticker
Name
Market Cap$
top bottom
WIT logo
WIT
Wipro Ltd
27.24B
LPL logo
LPL
LG Display Co Ltd
4.32B
CSAN logo
CSAN
Cosan SA
4.02B
COTY logo
COTY
Coty Inc
2.85B
RLX logo
RLX
RLX Technology Inc
2.75B
BTE logo
BTE
Baytex Energy Corp
2.64B
any penny stock?
Intellectia · 72 candidates
Market Cap: 50.00M - 2.00BPrice: <= $5.00Beta: ModerateRisk, HighRiskWeekly Average Turnover: >= 1,000,000Annual Revenue Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
BITF logo
BITF
Bitfarms Ltd
1.61B
BORR logo
BORR
Borr Drilling Ltd
1.34B
TUYA logo
TUYA
Tuya Inc
1.31B
TBLA logo
TBLA
Taboola.com Ltd
1.18B
BFLY logo
BFLY
Butterfly Network Inc
1.12B
ASST logo
ASST
Strive Inc
1.11B

Whales Holding CRON

A
Altria Group, Inc.
Holding
CRON
+14.45%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cronos Group Inc (CRON) stock price today?

The current price of CRON is 2.52 USD — it has increased 0

What is Cronos Group Inc (CRON)'s business?

Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.

What is the price predicton of CRON Stock?

Wall Street analysts forecast CRON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRON is2.72 USD with a low forecast of 2.30 USD and a high forecast of 3.14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cronos Group Inc (CRON)'s revenue for the last quarter?

Cronos Group Inc revenue for the last quarter amounts to 44.53M USD, increased 46.96

What is Cronos Group Inc (CRON)'s earnings per share (EPS) for the last quarter?

Cronos Group Inc. EPS for the last quarter amounts to -0.00 USD, decreased -100.00

How many employees does Cronos Group Inc (CRON). have?

Cronos Group Inc (CRON) has 356 emplpoyees as of March 10 2026.

What is Cronos Group Inc (CRON) market cap?

Today CRON has the market capitalization of 955.21M USD.